메뉴 건너뛰기




Volumn 339, Issue 7720, 2009, Pages 527-

QRISK validation and evaluation: Bespoke cohort studies needed

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

EID: 69949085802     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b3512     Document Type: Letter
Times cited : (4)

References (3)
  • 1
    • 68249129902 scopus 로고    scopus 로고
    • An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study
    • (7 July.)[Abstract/Free Full Text]
    • Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009;339:b2584. (7 July.)[Abstract/Free Full Text]
    • (2009) BMJ , vol.339
    • Collins, G.S.1    Altman, D.G.2
  • 3
    • 34447619161 scopus 로고    scopus 로고
    • Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study
    • DOI 10.1136/bmj.39261.471806.55
    • Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.[Abstract/ Free Full Text] (Pubitemid 47172233)
    • (2007) British Medical Journal , vol.335 , Issue.7611 , pp. 136-141
    • Hippisley-Cox, J.1    Coupland, C.2    Vinogradova, Y.3    Robson, J.4    May, M.5    Brindle, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.